The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, germ cell, and epithelial tumors containing amplification of CCND1.
R. F. Perini
Research Funding - Pfizer
A. DeMichele
Research Funding - Pfizer
D. J. Vaughn
No relevant relationships to disclose
M. Gallagher
No relevant relationships to disclose
W. Sun
No relevant relationships to disclose
B. J. Giantonio
No relevant relationships to disclose
U. R. Teitelbaum
No relevant relationships to disclose
S. Randolph
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
J. G. Christensen
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
R. D. Courtney
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
D. A. Pryma
No relevant relationships to disclose
C. R. Divgi
No relevant relationships to disclose
P. J. O'Dwyer
Research Funding - Pfizer (B)